ATE442845T1 - Verwendung von alkylfuranen zur herstellung eines antidiabetikums - Google Patents

Verwendung von alkylfuranen zur herstellung eines antidiabetikums

Info

Publication number
ATE442845T1
ATE442845T1 AT05773032T AT05773032T ATE442845T1 AT E442845 T1 ATE442845 T1 AT E442845T1 AT 05773032 T AT05773032 T AT 05773032T AT 05773032 T AT05773032 T AT 05773032T AT E442845 T1 ATE442845 T1 AT E442845T1
Authority
AT
Austria
Prior art keywords
alkylfurans
producing
antidiabetic drug
preventing
treating diabetes
Prior art date
Application number
AT05773032T
Other languages
English (en)
Inventor
Antoine Piccirilli
Philippe Msika
Nathalie Piccardi
Original Assignee
Expanscience Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expanscience Lab filed Critical Expanscience Lab
Application granted granted Critical
Publication of ATE442845T1 publication Critical patent/ATE442845T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Furan Compounds (AREA)
AT05773032T 2004-05-28 2005-05-27 Verwendung von alkylfuranen zur herstellung eines antidiabetikums ATE442845T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405782A FR2870742B1 (fr) 2004-05-28 2004-05-28 Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete, de l'obesite et pour le traitement cosmetique de la cellulite et de la surcharge ponderale
PCT/FR2005/001310 WO2005117856A1 (fr) 2004-05-28 2005-05-27 Utilisation d’alkyle furannes pour la preparation d’un medicament destine au traitement du diabete

Publications (1)

Publication Number Publication Date
ATE442845T1 true ATE442845T1 (de) 2009-10-15

Family

ID=34946318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05773032T ATE442845T1 (de) 2004-05-28 2005-05-27 Verwendung von alkylfuranen zur herstellung eines antidiabetikums

Country Status (11)

Country Link
US (1) US8859617B2 (de)
EP (1) EP1765323B1 (de)
JP (1) JP4795337B2 (de)
CN (3) CN1972661B (de)
AT (1) ATE442845T1 (de)
CA (1) CA2566970C (de)
DE (1) DE602005016680D1 (de)
ES (2) ES2331847T3 (de)
FR (1) FR2870742B1 (de)
MX (1) MXPA06013883A (de)
WO (1) WO2005117856A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889956B1 (fr) * 2005-08-30 2012-04-20 Expanscience Lab Utilisation d'au moins un 2-alkyle furane, a titre de principe actif depigmentant ou eclaircissant
US9072717B2 (en) * 2007-09-18 2015-07-07 Elc Management Llc Cosmetic compositions containing alpha glucosidase inhibitors and methods of use
WO2010065528A2 (en) * 2008-12-02 2010-06-10 Kreations By Kristin, L.C. Gymnema-containing lip balm compositions and associated methods
FR2949044B1 (fr) * 2009-08-12 2021-05-07 Expanscience Lab Composition comprenant une fraction d'insaponifiable
JP5818300B2 (ja) * 2010-12-27 2015-11-18 雪印メグミルク株式会社 ミルクセラミド含有食品及びその製造方法
FR2985665B1 (fr) * 2012-01-13 2015-10-02 Expanscience Lab Utilisation de peau d'avocat pour obtenir un insaponifiable d'avocat enrichi en hydrocarbures aliphatiques satures et en sterols
AU2014240950B2 (en) 2013-03-29 2018-11-01 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders
WO2017189865A1 (en) 2016-04-27 2017-11-02 Avoscience, Llc Lipidic furan, pyrrole, and thiophene compounds for use in the treatment of atrophic vaginitis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127592A (en) 1977-03-31 1978-11-28 Polak's Frutal Works, B.V. Process of the preparation of hydroxyfurenones
IL63632A (en) * 1980-08-27 1986-02-28 Merrell Dow Pharma Acylated furanyl and thienyl acrylic acids and process for their preparation
EP0110548B1 (de) 1982-10-29 1987-06-24 Plessey Overseas Limited Elektrisch leitende Dichtungen
FR2678614A1 (fr) * 1991-07-03 1993-01-08 Pharmascience Lab Compose presentant une activite en tant qu'inhibiteur de la collagenase et medicament le contenant.
FR2678632B1 (fr) 1991-07-03 1994-09-02 Pharmascience Lab Procede de preparation de l'insaponifiable d'avocat permettant d'ameliorer sa teneur en l'une de ses fractions dite h.
RU1838296C (ru) * 1991-11-27 1995-12-20 Всесоюзный научный центр по безопасности биологически активных веществ Производные арилсульфокислот, проявляющие гипогликемическую активность
US5468490A (en) * 1993-10-25 1995-11-21 Conkle & Olesten Lipidic furans useful for skin therapeutics
JPH08332061A (ja) 1995-06-07 1996-12-17 Sanki Shoji Kk アボカド葉茶とその飲料及び抽出液乾固物
WO1998000389A1 (en) * 1996-07-02 1998-01-08 Sang Sup Jew 2-hydroxypropionic acid derivative and its manufacturing method
JP4047441B2 (ja) 1998-03-05 2008-02-13 株式会社資生堂 脂質分解促進剤および痩身用皮膚外用剤
CA2334312A1 (en) * 1998-06-26 2000-01-06 Takara Shuzo Co., Ltd. Therapeutic agents
JP2000144170A (ja) * 1998-09-01 2000-05-26 Janifu Tekku:Kk 抗肥満及び内臓蓄積脂肪低減化機能を有する物質、及びその用途
DE19901502C1 (de) 1999-01-11 2000-09-21 Michael Schneider Anticellulitiszusammensetzung und ihre Verwendung
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
FR2798667B1 (fr) 1999-09-22 2001-12-21 Pharmascience Lab Procede d'extraction des composes furaniques et alcools gras polyhydroxyles de l'avocat, composition a base de et utilisation de ces composes en therapeutique, cosmetique et alimentaire
JP4693964B2 (ja) * 2000-08-07 2011-06-01 カゴメ株式会社 新規摂食抑制剤
JP2002212177A (ja) * 2000-11-14 2002-07-31 Takeda Chem Ind Ltd 脂質代謝改善剤
US7524969B2 (en) 2001-01-26 2009-04-28 Chugai Seiyaku Kabushiki Kaisha Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
JP2005232005A (ja) * 2001-07-02 2005-09-02 Maruha Corp 新規脂肪族化合物、合成方法、利用方法
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
AU2002364900A1 (en) 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
FR2841470B1 (fr) 2002-06-27 2006-01-13 Pharmascience Lab Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
US6994875B2 (en) 2002-07-29 2006-02-07 Laboratoires Expanscience Process for obtaining a furan lipid-rich unsaponifiable material from avocado
US6793946B2 (en) 2002-07-31 2004-09-21 Access Business Group International Llc. Composition and method for lowering cholesterol
FR2856294B1 (fr) 2003-06-18 2005-08-05 Expanscience Lab Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
US20050048144A1 (en) * 2003-08-29 2005-03-03 Xiao-Qing Han Herb extract-based cosmeceutical cream for controlling the blood sugar level of diabetes and methods for making it
ATE462431T1 (de) 2004-05-28 2010-04-15 Expanscience Lab Verwendung von furanalkylen zur herstellung eines arzneimittels für die behandlung von adipositas sowie kosmetische behandlung von übergewicht

Also Published As

Publication number Publication date
FR2870742A1 (fr) 2005-12-02
CA2566970C (fr) 2012-08-28
HK1100167A1 (zh) 2007-09-07
CN1972661B (zh) 2011-03-16
ES2331847T3 (es) 2010-01-18
EP1765323B1 (de) 2009-09-16
US8859617B2 (en) 2014-10-14
CN1960722B (zh) 2010-09-08
JP2008501003A (ja) 2008-01-17
CN1960723A (zh) 2007-05-09
FR2870742B1 (fr) 2008-03-14
EP1765323A1 (de) 2007-03-28
CN1960722A (zh) 2007-05-09
WO2005117856A1 (fr) 2005-12-15
CN1972661A (zh) 2007-05-30
JP4795337B2 (ja) 2011-10-19
ES2364153T3 (es) 2011-08-25
DE602005016680D1 (de) 2009-10-29
CA2566970A1 (fr) 2005-12-15
MXPA06013883A (es) 2007-01-26
CN1960723B (zh) 2010-09-08
US20080081837A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
ATE448732T1 (de) Sammlung von informationen zur aktivität und schlafqualität mit einem medizinprodukt
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
MY159562A (en) Adipose tissue derived stromal cells for the treatment of neurological disorders
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0414094A (pt) compostos de piperazina substituìdos usados como bloqueadores do canal de cálcio
MX2010001784A (es) Activadores novedosos de la glucocinasa.
WO2007024899A3 (en) Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
ATE442845T1 (de) Verwendung von alkylfuranen zur herstellung eines antidiabetikums
ZA200900444B (en) Thin film multilocular structure comprising collagen, material for tissue regeneration containing the same and method for producing the same
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
SE0102147D0 (sv) New methods
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
WO2005044334A3 (en) Colorful shielded reciprocating butterfly needle
ATE554144T1 (de) Verfahren zur herstellung von kationischen azoverbindungen
ITMO20040334A1 (it) Abbigliamento dotato di propieta' antiproiettile e anicoltello.
EP1800654A3 (de) Verringerung der Haaralterung
ATE388719T1 (de) Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE253905T1 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
ATE517631T1 (de) Prozess zur herstellung von ferutinin aus pflanzen der ferulafamilie
ATE416785T1 (de) Therapeutische anwendungen für c-peptid
DE60135911D1 (de) vERWENDUNG VON SULODEXIDE ZUR BEHANDLUNG VON DIABETISCHER NEPHROPATHIE
DE60213237D1 (de) Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
KR20170065169A (ko) 스마트 알람장치 및 스마트 알람장치를 이용한 기상 방법

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties